Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Long-Term Investments (2020 - 2024)

Editas Medicine (EDIT) has disclosed Long-Term Investments for 5 consecutive years, with $39.2 million as the latest value for Q2 2024.

  • Quarterly Long-Term Investments fell 18.5% to $39.2 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $39.2 million through Jun 2024, down 18.5% year-over-year, with the annual reading at $104.0 million for FY2023, 11.74% up from the prior year.
  • Long-Term Investments for Q2 2024 was $39.2 million at Editas Medicine, down from $80.6 million in the prior quarter.
  • The five-year high for Long-Term Investments was $120.1 million in Q4 2021, with the low at $39.2 million in Q2 2024.
  • Average Long-Term Investments over 5 years is $82.3 million, with a median of $85.5 million recorded in 2021.
  • The sharpest move saw Long-Term Investments surged 115.65% in 2021, then tumbled 40.68% in 2022.
  • Over 5 years, Long-Term Investments stood at $109.7 million in 2020, then rose by 9.49% to $120.1 million in 2021, then fell by 22.47% to $93.1 million in 2022, then increased by 11.74% to $104.0 million in 2023, then plummeted by 62.32% to $39.2 million in 2024.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $39.2 million, $80.6 million, and $104.0 million for Q2 2024, Q1 2024, and Q4 2023 respectively.